553. Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Treatment with Monoclonal Antibody Therapy (MAT) in the Outpatient Setting

BACKGROUND: Monoclonal antibody therapy (MAT) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with positive SARS-CoV-2 viral testing and at high risk for progression to severe COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Courtney, Lustberg, Mark, Sobhanie, Mohammad Mahdee, Lehman, Joy, Reed, Erica E, Kman, Nicholas E, Conroy, Mark, Dick, Michael, Allen, James N, Parsons, Jonathan, Malvestutto, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643966/
http://dx.doi.org/10.1093/ofid/ofab466.751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643966/
http://dx.doi.org/10.1093/ofid/ofab466.751

Ejemplares similares